Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | ROS1 | P08922 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7495208 | 0.82 | KDM4E (0.40) | ERN1CASP1CA1CA2KDM4E | |
| SCHEMBL28221345 | 0.82 | DGAT1 (0.52) | DGAT1ERN1KMT2AATMPLK4 | |
| SCHEMBL5802725 | 0.80 | DGAT1 (0.46) | DGAT1KMT2AATMCASP1KDM4E | |
| SCHEMBL27775492 | 0.80 | KMT2A (0.50) | DGAT1KMT2AATMCASP1CA12 | |
| SCHEMBL25211259 | 0.78 | KMT2A (0.40) | DGAT1KMT2AATMCASP1KDM4E | |
| SCHEMBL16122584 | 0.78 | DGAT1 (0.48) | DGAT1ERN1KMT2AATMPLK4 | |
| SCHEMBL149886 | 0.77 | DGAT1 (0.47) | DGAT1ERN1PARP15PARP10KIF11 | |
| SCHEMBL18786842 | 0.77 | ERN1 (0.43) | DGAT1ERN1KMT2AATMCASP1 | |
| SCHEMBL30880334 | 0.77 | DGAT1 (0.47) | DGAT1ERN1PARP15PARP10KIF11 | |
| SCHEMBL17711410 | 0.77 | ABL1 (0.44) | ATMCASP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112192-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3887373-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113227092-A | Compounds and methods of use thereof for treating cancer | 亚瑞克西斯制药公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020113071-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112192-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | KRAS, NRAS, HRAS | DGAT1 2746/4885ERN1 723/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.